Skin application of glutathione and iron sulfate can inhibit elicitation of allergic contact dermatitis from hexavalent chromium.
Administration, Cutaneous
Adult
Aged
Aged, 80 and over
Allergens
/ adverse effects
Chromium
/ adverse effects
Dermatitis, Allergic Contact
/ diagnosis
Dermatologic Agents
/ therapeutic use
Female
Ferrous Compounds
/ therapeutic use
Glutathione
/ therapeutic use
Humans
Male
Middle Aged
Patch Tests
Secondary Prevention
/ methods
Skin Cream
/ therapeutic use
Treatment Outcome
Cr(III)
Cr(VI)
allergic contact dermatitis
barrier cream
chromate
contact allergy
delayed hypersensitivity
hexavalent chromium
patch testing
prevention
trivalent chromium
Journal
Contact dermatitis
ISSN: 1600-0536
Titre abrégé: Contact Dermatitis
Pays: England
ID NLM: 7604950
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
05
08
2019
revised:
27
09
2019
accepted:
28
09
2019
pubmed:
5
10
2019
medline:
30
5
2020
entrez:
5
10
2019
Statut:
ppublish
Résumé
Allergic contact dermatitis (ACD) caused by hexavalent chromium, Cr(VI), is often severe and difficult to treat. The most common source of exposure to Cr(VI) in Sweden used to be cement, and more recently leather. The contact allergy can be diminished or inhibited if the exposure is decreased or ceases. Barrier creams against different kinds of allergens have been investigated for their protective properties which may offer protection against Cr(VI) exposure. To investigate the capacity of formulas containing glutathione (GSH) and iron sulfate to inhibit elicitation of ACD in Cr(VI)-allergic individuals when exposed to Cr(VI). In 18 Cr(VI)-allergic volunteers the back was divided into eight patch test areas which were treated with preparations of possible barrier creams, prior to patch testing with a dilution series of potassium dichromate and a buffered extract of cement. A significant reduction in reactivity to Cr(VI) and cement extract on skin treated with formulas containing GSH or iron sulfate was noticed, compared with untreated skin. Formulas containing GSH or iron sulfate in barrier creams inhibit ACD in individuals allergic to Cr(VI) when applied before exposure to Cr(VI) and cement extract.
Sections du résumé
BACKGROUND
BACKGROUND
Allergic contact dermatitis (ACD) caused by hexavalent chromium, Cr(VI), is often severe and difficult to treat. The most common source of exposure to Cr(VI) in Sweden used to be cement, and more recently leather. The contact allergy can be diminished or inhibited if the exposure is decreased or ceases. Barrier creams against different kinds of allergens have been investigated for their protective properties which may offer protection against Cr(VI) exposure.
OBJECTIVES
OBJECTIVE
To investigate the capacity of formulas containing glutathione (GSH) and iron sulfate to inhibit elicitation of ACD in Cr(VI)-allergic individuals when exposed to Cr(VI).
METHODS
METHODS
In 18 Cr(VI)-allergic volunteers the back was divided into eight patch test areas which were treated with preparations of possible barrier creams, prior to patch testing with a dilution series of potassium dichromate and a buffered extract of cement.
RESULTS
RESULTS
A significant reduction in reactivity to Cr(VI) and cement extract on skin treated with formulas containing GSH or iron sulfate was noticed, compared with untreated skin.
CONCLUSION
CONCLUSIONS
Formulas containing GSH or iron sulfate in barrier creams inhibit ACD in individuals allergic to Cr(VI) when applied before exposure to Cr(VI) and cement extract.
Substances chimiques
Allergens
0
Dermatologic Agents
0
Ferrous Compounds
0
Chromium
0R0008Q3JB
chromium hexavalent ion
18540-29-9
ferrous sulfate
39R4TAN1VT
Glutathione
GAN16C9B8O
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
45-53Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Avnstorp C. Prevalence of cement eczema in Denmark before and since addition of ferrous sulfate to Danish cement. Acta Derm Venereol. 1989;69:151-155.
Hansen MB, Menné T, Johansen JD. Cr(III) reactivity and foot dermatitis in Cr(VI) positive patients. Contact Dermatitis. 2006;54:140-144.
Fregert S, Gruvberger B, Sandahl E. Reduction of chromate in cement by iron sulfate. Contact Dermatitis. 1979;5:39-42.
European Parliament, Council of the European Union. Directive 2003/53/EC of the European Parliament and of the Council of June 18, 2003 amending for the 26th time Council Directive 76/769/EEC relating to restrictions on the marketing and use of certain dangerous substances and preparations (nonylphenol, nonylphenol ethoxylate and cement). Off J Eur Union. 2003; p. L178/24-L178/27
Lejding T, Mowitz M, Isaksson M, et al. A retrospective investigation of hexavalent chromium allergy in southern Sweden. Contact Dermatitis. 2018;78:386-392.
Schmidt M, Goebler M. Immunology of metal allergies. J Dtsch Dermatol Ges. 2015;13:653-660.
Bruze M, Gruvberger B, Hradil E. Chromate sensitization and elicitation from cement with iron sulfate. Acta Derm Venereol. 1990;70:160-162.
Mowitz M, Zimerson E, Hauksson I, Pontén A. Chromate and amine contact allergies in workers manufacturing precast concrete elements. Contact Dermatitis. 2016;75:363-369.
Submitted. Lejding T, Engfeldt M, Bruze M, et al. Can reducing cosmetic substances help prevent chromate contact allergy?
Submitted. Lejding T, Svedman C, Engfeldt M, et al. Barrier creams may not always perform as expected.
Bregnbak D, Johansen JD, Jellesen MS, Zachariae C, Thyssen JP. Chromium (VI) release from leather and metals can be detected with a diphenylcarbazide spot test. Contact Dermatitis. 2015;73:281-288.
Frick-Engfeldt M, Gruvberger B, Isaksson M, Hauksson I, Pontén A, Bruze M. Comparison of three different techniques for application of water solutions to Finn Chambers®. Contact Dermatitis. 2010;63:284-288.
Fregert S. Manual of contact dermatitis. 2nd ed. Copenhagen: Munksgaard; 1981 138p.
Johansen JD, Aalto-Korte K, Agner T, et al. European Society of Contact Dermatitis guideline for diagnostic patch testing - recommendations on the best practice. Contact Dermatitis. 2015;73:195-211.
Hindsén M, Bruze M, Christensen OB. The significance of previous allergic contact dermatitis for elicitation of delayed hypersensitivity to nickel. Contact Dermatitis. 1997;37:101-106.
Wong CC, Gamboni SE, Palmer AM, Nixon RL. Occupational allergic contact dermatitis to chromium from cement: estimating the size of the problem in Australia. Australas J Dermatol. 2015;56:290-293.
Goon ATJ, Goh CL. Metal allergy in Singapore. Contact Dermatitis. 2005;52:130-132.
Lim YL, Goon A. Occupational skin diseases in Singapore 2003-2004: an epidemiologic update. Contact Dermatitis. 2007;56:157-159.
Akasya-Hillenbrand E, Özkaya-Bayzit E. Patch test results in 542 patients with suspected contact dermatitis in Turkey. Contact Dermatitis. 2002;46:17-23.
Hedberg YS, Gumulka M, Lind ML, Matura M, Lidén C. Severe occupational chromium allergy despite cement legislation. Contact Dermatitis. 2014;70:321-323.
D. Bregnbak and C. Avnstorp. Kanerva's Occupational Dermatology, Springer International Publishing AG; 2018.
Teichmann A, Jacobi U, Waibler E, Sterry W, Lademann J. An in vivo model to evaluate the efficacy of barrier creams on the level of skin penetration on chemicals. Contact Dermatitis. 2006;54:5-13.
Romaguera C, Grimalt F, Vilaplana J, Carreras E. Formulations of a barrier cream against chromate. Contact Dermatitis. 1985;13:49-52.
Gruvberger B, Bruze M. Can glutathione-containing emollients inactivate methylchloroisothiazolinone/methylisothiazolinone? Contact Dermatitis. 1998;38:261-265.
Isaksson M. Successful inhibition of allergic contact dermatitis caused by methylchloroisothiazolinone/methylisothiazolinone with topical glutathione. Contact Dermatitis. 2015;73:126-128.
Isaksson M, Niklasson B. Allergic contact dermatitis from Nickel is prevented using a novel barrier cream. Contact Dermatitis. 2016;75:68.
Wöhrl S, Kriechbaumer N, Hemmer W, et al. A cream containing the chelator DTPA (diethylenetriaminepenta-acetic acid) can prevent contact allergic reactions to metals. Contact Dermatitis. 2001;44:224-228.
Stocks SJ, McNamee R, Turner S, Carder M, Agius RM. Has European legislation to reduce exposure to chromate in cement been effective in reducing the incidence of allergic contact dermatitis attributed to chromate in the UK? Occup Environ Med. 2012;69:150-152.
Geier J, Krautheim A, Uter W, Lessmann H, Schnuch A. Occupational contact allergy in the building trade in Germany: influence of preventive measures and changing exposure. Int Arch Occup Environ Health. 2011;84:403-411.
Fregert S, Björkner B, Bruze M, Gruvberger B, Isaksson M, Zimerson E. Yrkesoch Miljödermatologi. Andra upplagan. Lund: Studentlitteratur; 2011.
Irvine C, Pugh CE, Hansen EJ, Rycroft RJ. Cement dermatitis in underground workers during construction of the Channel Tunnel. Occup Med. 1994;44:17-23.
Buters J, Biedermann T. Chromium(VI) contact dermatitis: getting closer to understanding the underlying mechanisms of toxicity and sensitization! J Invest Dermatol. 2017;137:274-277.
Siegenthaler U, Laine A, Polak L. Studies on contact sensitivity to chromium in the guinea pig. The role of valence in the formation of the antigenic determinant. J Invest Dermatol. 1983;80:44-47.